Mérieux : JH389 est un produit probiotique, non un médicament, et présente de nombreuses limitations en tant que complément alimentaire.

People Finance News, 30 March: Meinuo Hua (603538) issued on 30 March an announcement regarding abnormal stock price fluctuations, JH389 is a probiotic product, not a medicine, and as such has many limitations as a dietary supplement. The company’s in-development product JH389 is a probiotic; in the future, it plans to launch it as a dietary supplement and it is currently still in the research and trial stage. The earlier trial data had limitations. The sample size for the JH389 probiotic product in the domestic trials was 28 cases, conducted over an 8-week small-scale, limited-scope feeding trial. Because the sample size is relatively limited, the general applicability of its conclusions needs to be further verified in larger-scale populations, and the certainty of its conclusions is not yet sufficient. The product faces relatively intense competition. Non-medicinal weight-loss products include many categories that widely participate in competition, such as probiotic products, other dietary supplements, health foods, meal replacements, and functional foods. At present, there are numerous market participants, categories are becoming increasingly diverse, and the competitive landscape of the industry is relatively intense.